Aviva PLC Vertex Pharmaceuticals Inc Transaction History

Aviva PLC

$34.3 Billion
Q2 2024

A detailed history of Aviva PLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Aviva PLC holds 121,917 shares of VRTX stock, worth $61.3 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares

121,917

Previous 98,001 24.4%

Holding current value

$61.3 Million

Previous $41 Million 39.49%

% of portfolio

0.17%

Previous 0.14%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 02, 2024	BUY	$392.81 - $485.53 $9.39 Million - $11.6 Million	23,916 Added 24.4%	121,917 $57.1 Million
Q1 2024 May 14, 2024	SELL	$407.69 - $446.08 $11.8 Million - $12.9 Million	-28,982 Reduced 22.82%	98,001 $41 Million
Q4 2023 Feb 09, 2024	BUY	$343.0 - $410.68 $5.95 Million - $7.13 Million	17,357 Added 15.83%	126,983 $51.7 Million
Q3 2023 Nov 13, 2023	BUY	$338.18 - $362.46 $2.98 Million - $3.2 Million	8,816 Added 8.75%	109,626 $38.1 Million
Q2 2023 Aug 10, 2023	SELL	$314.42 - $351.91 $17.5 Million - $19.6 Million	-55,572 Reduced 35.54%	100,810 $35.5 Million
Q1 2023 May 12, 2023	BUY	$283.23 - $323.1 $1.17 Million - $1.33 Million	4,121 Added 2.71%	156,382 $49.3 Million
Q4 2022 Feb 09, 2023	SELL	$285.76 - $321.48 $5.36 Million - $6.03 Million	-18,744 Reduced 10.96%	152,261 $44 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $6.52 Million - $7.28 Million	-23,816 Reduced 12.22%	171,005 $49.5 Million
Q2 2022 Aug 04, 2022	BUY	$234.96 - $292.55 $11.1 Million - $13.8 Million	47,073 Added 31.86%	194,821 $54.9 Million
Q1 2022 May 13, 2022	BUY	$221.42 - $260.97 $12 Million - $14.2 Million	54,224 Added 57.98%	147,748 $38.6 Million
Q4 2021 Feb 10, 2022	SELL	$177.01 - $223.45 $1.53 Million - $1.93 Million	-8,617 Reduced 8.44%	93,524 $20.5 Million
Q3 2021 Nov 12, 2021	BUY	$181.39 - $202.99 $1.09 Million - $1.22 Million	6,025 Added 6.27%	102,141 $18.5 Million
Q2 2021 Aug 10, 2021	BUY	$187.49 - $221.1 $1.72 Million - $2.02 Million	9,156 Added 10.53%	96,116 $19.4 Million
Q1 2021 May 13, 2021	SELL	$207.02 - $241.31 $86,120 - $100,384	-416 Reduced 0.48%	86,960 $18.7 Million
Q4 2020 Feb 10, 2021	BUY	$207.01 - $276.09 $731,780 - $975,978	3,535 Added 4.22%	87,376 $20.7 Million
Q3 2020 Nov 12, 2020	SELL	$255.65 - $303.1 $693,322 - $822,007	-2,712 Reduced 3.13%	83,841 $22.8 Million
Q2 2020 Aug 13, 2020	SELL	$225.48 - $295.8 $1.02 Million - $1.34 Million	-4,520 Reduced 4.96%	86,553 $25.1 Million
Q1 2020 May 14, 2020	BUY	$199.77 - $247.81 $196,573 - $243,845	984 Added 1.09%	91,073 $21.7 Million
Q4 2019 Feb 10, 2020	SELL	$166.71 - $223.91 $84,021 - $112,850	-504 Reduced 0.56%	90,089 $19.7 Million
Q3 2019 Nov 12, 2019	SELL	$166.23 - $187.09 $589,784 - $663,795	-3,548 Reduced 3.77%	90,593 $15.3 Million
Q2 2019 Jul 30, 2019	SELL	$164.61 - $190.37 $385,187 - $445,465	-2,340 Reduced 2.43%	94,141 $17.3 Million
Q1 2019 May 14, 2019	BUY	$163.73 - $194.7 $28,652 - $34,072	175 Added 0.18%	96,481 $17.7 Million
Q4 2018 Feb 12, 2019	SELL	$151.91 - $192.21 $4.02 Million - $5.09 Million	-26,489 Reduced 21.57%	96,306 $16 Million
Q3 2018 Nov 13, 2018	SELL	$167.73 - $192.74 $730,128 - $838,997	-4,353 Reduced 3.42%	122,795 $23.7 Million
Q2 2018 Aug 01, 2018	SELL	$145.72 - $169.96 $121,676 - $141,916	-835 Reduced 0.65%	127,148 $21.6 Million
Q1 2018 May 14, 2018	SELL	$151.6 - $177.13 $1.9 Million - $2.22 Million	-12,550 Reduced 8.93%	127,983 $20.9 Million
Q4 2017 Feb 13, 2018	SELL	$137.28 - $155.55 $2.41 Million - $2.73 Million	-17,545 Reduced 11.1%	140,533 $21.1 Million
Q3 2017 Nov 13, 2017	BUY	$148.13 - $162.24 $506,604 - $554,860	3,420 Added 2.21%	158,078 $24 Million
Q2 2017 Aug 07, 2017	BUY	N/A	154,658	154,658 $19.9 Million

Others Institutions Holding VRTX

# of Institutions

1,716

Shares Held

225M

Call Options Held

1.19M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aviva PLC, based on Form 13F filings with the SEC.

News

Stay updated on Aviva PLC with notifications on news.

Account